Cemsidomide

Cemsidomide is an investigational oral cereblon-modulating protein degrader of IKZF1/3, transcription factors foundational to multiple myeloma biology. Data from the fully enrolled Phase 1 trial show cemsidomide’s differentiated safety and tolerability profile and potentially class-leading anti-myeloma activity that supports the potential for durable outcomes.

IKZF1/3 Degradation to Treat Multiple Myeloma

Multiple myeloma cells rely on IKZF1/3 for survival. Degrading IKZF1/3 leads to myeloma cell death and drives anti-myeloma activity. IKZF1/3 also directly regulate the activity of IRF4, a transcription factor that regulates downstream immune cell activation. When IKZF1/3 are degraded, it leads to downregulation of IRF4, which promotes myeloma cell death, as well as T-cell activation.

IKZF1/3 degradation is a clinically validated mechanism of action and a foundational therapy for multiple myeloma, used across multiple treatment lines and combinations because it kills myeloma cells and promotes T-cell activation.

Scientific Presentations and Publications

T- and NK-cell Immunomodulatory Reprogramming by Cemsidomide, a Novel and Potent MonoDAC® Degrader, in Relapsed/Refractory Multiple Myeloma: Biomarker Results from CFT7455-1101 Arm B2 Cohort

Updated Results of a Phase 1 First-in-Human Study of Cemsidomide, a Novel MonoDAC® Degrader, with Dexamethasone (DEX) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

MOMENTUM: A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma

Population Pharmacokinetics and Exposure-response Analysis of Cemsidomide in Patients with Relapsed/Refractory Multiple Myeloma and Non-Hodgkin’s Lymphoma

Updated Results of a Phase 1 First-in-Human Study of Cemsidomide (CFT7455), a Novel MonoDAC® Degrader, with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma

Initial Results of a Phase 1 First-in-Human Study of CFT7455 (Cemsidomide), a Novel MonoDAC® Degrader, with Dexamethasone (Dex) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Initial Results of a Phase 1 First-in-Human Study of Cemsidomide (CFT7455), a Novel MonoDAC® Degrader, in Patients with Non-Hodgkin’s Lymphoma

CFT7455, a novel IKZF1/3 degrader, enhances the anti-myeloma activity of monoclonal and bispecific antibodies by augmenting immune responses

CFT7455: A novel IKZF1/3 degrader, demonstrates potent anti-tumor activity in peripheral and CNS models of non-Hodgkin’s lymphoma as a single agent or in combination with clinically approved agents

The Discovery and Characterization of CFT7455: A Potent and Selective Degrader of IKZF1/3 for the Treatment of Relapsed/Refractory Multiple Myeloma

AACR Poster Presentation: CFT7455 Phase 1/2 Cohort A

A Phase 1 Study of CFT7455, a Novel Degrader of IKZF1/3, in Multiple Myeloma and Non-Hodgkin Lymphoma

CFT7455: A novel, IKZF1/3 Degrader That Demonstrates Potent Tumor Regression in a Spectrum of Non-Hodgkin Lymphoma Xenograft Models

CFT7455: A novel, IKZF1/3 degrader that demonstrates potent tumor regression in IMiD-resistant multiple myeloma (MM) xenograft models